This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Holding Humana (HUM) in Your Portfolio is a Prudent Move
by Zacks Equity Research
Banking on better membership and strategic initiatives, Humana (HUM) holds immense potential to reap benefits for investors.
Here's Why Humana (HUM) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Humana (HUM) Taps Debt Market With Senior Note Pricing
by Zacks Equity Research
Humana (HUM) exhibits monetary discretion by pricing senior secured notes to procure funds.
Humana (HUM) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Acadia Healthcare (ACHC) JV Adds Service Line, Ups Bed Capacity
by Zacks Equity Research
Acadia Healthcare (ACHC) operated (through a JV) Southcoast Behavioral Health includes a pediatric service line and increases bed capacity to 192.
Centene (CNC) Wins Contract to Serve Medicaid Members in Indiana
by Zacks Equity Research
Centene's (CNC) Indiana subsidiary receives a contract from the Indiana Department of Administration, thereby continuing to serve the unique health needs of Indiana communities.
Is Humana (HUM) a Great Stock for Value Investors?
by Zacks Equity Research
Is Humana (HUM) a great pick from the value investor's perspective right now? Read on to know more.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTCS
Why Is Humana (HUM) Up 2.3% Since Last Earnings Report?
by Zacks Equity Research
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cigna (CI) Unveils '22 Capital Deployment Plans, Shares Up
by Zacks Equity Research
Cigna's (CI) shares gain on plans to deploy capital via share buybacks and targeted bolt-on acquisitions, which reflect its financial strength.
UnitedHealth Group (UNH) Bolsters Presence With Contract Win
by Zacks Equity Research
UnitedHealth Group's (UNH) unit UnitedHealthcare receives a contract from the District of Columbia aimed at improving health outcomes of District Dual Choice program enrollees in the district.
Humana (HUM) Okays Dividend Hike, Boosts Shareholder Value
by Zacks Equity Research
Humana's (HUM) recent dividend hike highlights its sound financial position and sincere efforts to reward shareholders.
Humana (HUM) to Support Eligible Medicaid Members in Louisiana
by Zacks Equity Research
Humana (HUM) is picked by the Louisiana Department of Health for a contract win to help serve the Medicaid members in Louisiana.
Centene (CNC) Boosts Presence in Louisiana With Contract Win
by Zacks Equity Research
Centene's (CNC) latest contract renewal tends to improve health outcomes of Medicaid members of Louisiana.
Cigna (CI) Q4 Earnings Beat on Robust Cigna Healthcare Unit
by Zacks Equity Research
Cigna's (CI) fourth-quarter results benefit from strong medical customer growth. A solid outlook for 2022 when compared to the 2021 level remains noteworthy.
Company News for Feb 3, 2022
by Zacks Equity Research
Companies In The News Are: DHI, TMO, HUM, MPC.
Humana (HUM) Q4 Earnings Beat Estimates on Membership Growth
by Zacks Equity Research
Humana (HUM) is taking multiple initiatives like cost savings and others to generate $1 billion additional value to fund the Medicare Advantage business and boost Healthcare Services capabilities.
Humana (HUM) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 0.81% and 0.62%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Retail Loss to Affect Humana's (HUM) Q4 Earnings: Here's How
by Zacks Equity Research
Humana's (HUM) fourth-quarter results are likely to reflect growth in medical membership.
Humana (HUM) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Humana (HUM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Humana (HUM) to Buy Back Shares of $1B to Add Shareholder Value
by Zacks Equity Research
Humana (HUM) to buy back shares worth $1 billion as part of its $3-billion share repurchase plan announced in February 2021. This suggests its commitment toward delivering a long-term shareholder value.
UnitedHealth (UNH) Unit Invests to Improve Members' Eye Health
by Zacks Equity Research
UnitedHealth Group's (UNH) business, UnitedHealthcare, offers discount programs and invests in school districts in an effort to improve the eye health of its vision members.
Humana (HUM) Cuts Medicare Enrollment Outlook, Tumbles 19.4%
by Zacks Equity Research
Humana (HUM) expects Group Medicare Advantage membership to remain flat in 2022, with competitive pricing possibly playing a crucial role.
Humana (HUM) Enhances Value-Based Care With Vancouver Clinic
by Zacks Equity Research
Humana (HUM) collaborates with Vancouver Clinic to boost its Medicare Advantage portfolio.
Molina Healthcare (MOH) Buys Cigna's TX Medicaid Contracts
by Zacks Equity Research
Molina Healthcare (MOH) purchases the Texas Medicaid contracts of Cigna to bolster its presence in the Texas region.